In a transformative move within the life sciences domain, Thermo Fisher Scientific Inc. is set to acquire proteomics pioneer Olink Holding AB for a compelling cash deal of $26 per share, tallying to a transactional value of around $3.1 billion. This offer marks a 74% premium on Olink’s ADS (American Depositary Shares) closing price from […]
Thermo Fisher Scientific, an American analytical laboratory instrument manufacturing company, has closed the previously announced acquisition of The Binding Site Group, a UK- based diagnostic products manufacturer, for £2.3 billion ($2.8 billion) in cash. The acquisition complements and adds to Thermo Fisher Scientific’s existing specialty diagnostics offering in oncology. The Binding Site offers specialty diagnostic […]
Thermo Fisher Scientific has agreed to acquire The Binding Site Group, a UK-based specialist protein diagnostics company, for £2.25 billion ($2.6 billion) in an all-cash deal from a shareholder consortium led by Nordic Capital. The Binding Site Group offers specialty diagnostic assays and instruments to help in the diagnosis and management of immune system disorders […]
Thermo Fisher Scientific has agreed to acquire PPD, a US-based clinical research services provider, for $47.50 per share or $20.9 billion. The consideration includes assumption of nearly $3.5 billion of the contract research organization’s net debt. Based in North Carolina, PPD caters to the pharma and biotech industry with a variety of clinical research and […]
Thermo Fisher Scientific has scrapped its previously planned $11.5 billion acquisition of Qiagen after its offer to buy all of the ordinary shares of the latter lapsed. The US life sciences company announced the acquisition of the Netherlands-based provider of molecular diagnostics and sample preparation technologies in March 2020 in a move to expand specialty […]
US life sciences company Thermo Fisher Scientific said that it will collaborate with China-based WuXi Diagnostics and Mayo Clinic to develop a total antibodies Covid-19 test called the Thermo Scientific OmniPath COVID-19 Total Antibody ELISA test. The new antibody test development is said to emerge from an ongoing partnership between the three organizations, which includes […]
Thermo Fisher acquisition of Qiagen : US life sciences company Thermo Fisher Scientific has agreed to acquire Qiagen, a Netherlands-based provider of molecular diagnostics and sample preparation technologies in an all-cash deal worth around $11.5 billion. The deal includes the assumption of nearly Qiagen’s $1.4 billion of net debt by the US firm. Thermo Fisher […]
Thermo Fisher Scientific has been granted an emergency use authorization (EUA) for its coronavirus diagnostic test from the US Food and Drug Administration (FDA). The FDA authorization allows Thermo Fisher Scientific’s COVID-19 diagnostic test that can be immediately used by CLIA high-complexity laboratories in the US for the detection of nucleic acid from SARS-CoV-2, the […]
Global life sciences company Thermo Fisher Scientific has agreed to acquire Massachusetts-based Brammer Bio from Ampersand Capital Partners for about $1.7 billion in cash. Brammer Bio is a viral vector contract development and manufacturing organization (CDMO) serving bipharma companies seeking to develop and commercialize gene therapies. The CDMO was formed in 2016 through the merger […]